Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic kidney disease (CKD) and type 2 diabetes in the FIDELIO-DKD and FIGARO-DKD phase 3 studies. Effects of finerenone on outcomes in patients taking sodium–glucose cotransporter 2 inhibitors (SGLT2is) were...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossing, Peter, Anker, Stefan D., Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M., Birkenfeld, Andreas L., McGill, Janet B., Rosas, Sylvia E., Joseph, Amer, Gebel, Martin, Roberts, Luke, Scheerer, Markus F., Bakris, George L., Agarwal, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862372/
https://www.ncbi.nlm.nih.gov/pubmed/35972218
http://dx.doi.org/10.2337/dc22-0294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862372/
https://www.ncbi.nlm.nih.gov/pubmed/35972218
http://dx.doi.org/10.2337/dc22-0294

Ejemplares similares